

primary studies - published RCT

The impact of probiotics on pulmonary, gastrointestinal, and growth outcomes in pediatric cystic fibrosis: a randomized controlled trial.

Code: PM40437397 Year: 2025 Date:

Author: Rahmani P

Study design (if review, criteria of inclusion for studies)

Double-blind randomized clinical trial

Participants

110 CF patients were examined.

Interventions

Probiotic consumption. Patients were divided into two equal groups of 55 subjects. Patients in the probiotic group consumed Lactobacillus reuteri at the rate of 10(8) CFU/d for one month, and the control group received a placebo.

Outcome measures

Pulmonary, gastrointestinal, and growth-related outcomes as well as quality of life were assessed after one month of intervention as well as at three-month follow-up.

Main results

The results of our study showed that in both intervention and control groups, weight increases significantly after 12 weeks ($P\hat{a} \in \mathbb{R}^{2} = \hat{a} = \hat{a$

Authors' conclusions

In general, treatment with probiotics improved the quality of life in patients with CF. However, no significant effect was observed on pulmonary, gastrointestinal, and growth-related outcomes.

http://dx.doi.org/10.1186/s12887-025-05789-0

See also

BMC Pediatr. 2025 May 28;25(1):430. doi: 10.1186/s12887-025-05789-0.

Keywords

Adolescent; Child; Lactobacillus; Probiotics; Supplementation; Oral; Immunoregulatory; pharmacological_intervention; Adult;